Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Blood (2017) 130 (Supplement 1): 2008.

https://doi.org/10.1182/blood.V130.Suppl_1.2008.2008

Published: 2017

Journal Articles

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood (2017) 130 (15): 1772–1774.

https://doi.org/10.1182/blood-2017-07-795302

Published: 2017

Journal Articles

Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry

Blood (2016) 128 (22): 3451.

https://doi.org/10.1182/blood.V128.22.3451.3451

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center

Yizel Elena Paz Nuñez, Beatriz Aguado Bueno, Isabel vicuña Andrés, Ángela Figuera Álvarez, Miriam González-Pardo, Rafael de la Cámara Llanzá, Valle Gómez García de Soria, Reyes Arranz Sáez, MD, Alvaro Arriero García, Elena Jiménez Barral, Susie Veramendi Zavala, Adrian Alegre

Blood (2015) 126 (23): 5536.

https://doi.org/10.1182/blood.V126.23.5536.5536

Published: 2015

Journal Articles

Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

Blood (2015) 126 (23): 521.

https://doi.org/10.1182/blood.V126.23.521.521

Published: 2015

Journal Articles

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Evelyn Acuña Cruz, MD, Jimena Cannata Ortiz, MD, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz Sáez, MD

Blood (2015) 126 (23): 5106.

https://doi.org/10.1182/blood.V126.23.5106.5106

Published: 2015

Journal Articles

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Blood (2015) 126 (23): 3944.

https://doi.org/10.1182/blood.V126.23.3944.3944

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Blood (2015) 126 (23): 4403.

https://doi.org/10.1182/blood.V126.23.4403.4403

Published: 2015

Journal Articles

High Dose Therapy with Autologous Stem Cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 Patients of Geltamo Spanish Group Suggests That FL Might be Cured, Even in High-Risk Patients

Blood (2014) 124 (21): 675.

https://doi.org/10.1182/blood.V124.21.675.675

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Jimena Cannata-Ortiz, MD, Concepción Nicolás, MD, Ana García-Noblejas, MD, Javier Lopez, Pilar Sabin, Pilar Zamora, Maria José Requena, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 4465.

https://doi.org/10.1182/blood.V124.21.4465.4465

Published: 2014

Journal Articles

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Blood (2014) 124 (21): 2524.

https://doi.org/10.1182/blood.V124.21.2524.2524

Published: 2014

Journal Articles

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Miriam González-Pardo, Carlos Fernández-Arandojo, Jimena Cannata, Beatriz Aguado, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 5897.

https://doi.org/10.1182/blood.V124.21.5897.5897

Published: 2014

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up

Rafael F. Duarte, MD, PhD, Ariane Boumendil, PhD, Francesco Onida, MD, Ian H Gabriel, Dr, Reyes Arranz, MD, William Arcese, MD, Xavier Poire, MD, Guido Kobbe, MD, Franco Narni, MD, Agostino Cortelezzi, MD, Eduardo Olavarría, MD, Norbert Schmitz, M.D. Ph.D., Anna Sureda, MD, Peter Dreger, MD

Blood (2013) 122 (21): 2094.

https://doi.org/10.1182/blood.V122.21.2094.2094

Published: 2013

Journal Articles

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Blood (2012) 120 (21): 3142.

https://doi.org/10.1182/blood.V120.21.3142.3142

Published: 2012

Journal Articles

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Antonio Salar, MD, Eva Domingo-Domenech, MD, Carlos Panizo, Concepción Nicolás, MD, Joan Bargay, Ana Muntanola, MD, Miguel Canales, Jose Luis Bello, MD, juan Manuel Sancho, Sr., MD, Jose Francisco Tomas, MD, María José Rodriguez, MD, Francisco-Javier Penalver, Luis Palomera, MD, Carlos Grande, José J Sánchez-Blanco, MD, Reyes Arranz, MD, Eulogio Conde, Dolores Caballero, MD, Carlos Montalban

Blood (2012) 120 (21): 3691.

https://doi.org/10.1182/blood.V120.21.3691.3691

Published: 2012

Journal Articles

Prognostic Value of Interim PET/CT in Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL). Experience of the Spanish Geltamo Group

Mónica Coronado, Emilia Pardal, Rosa Couto, Fatima de la Cruz, Carlos Panizo, Carlos Grande, Reyes Arranz, MD, María José Ramirez, Roberto Hernández, Alejandro Martin, Dolores Caballero, MD

Blood (2012) 120 (21): 5076.

https://doi.org/10.1182/blood.V120.21.5076.5076

Published: 2012

Journal Articles

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Ana García-Noblejas, MD, Belén Navarro Matilla, MD, Carolina Da Silva Rodriguez, Raquel De Oña Navarrete, MD, María José Ramirez Sánchez, MD, Concepción Nicolás, MD, Ricardo Pérez Fernández, Blanca Sanchez Gonzalez, MD, Eva Domingo-Domènech, MD, Jose Javier Sanchez Blanco, MD, Jimena Cannata-Ortiz, MD, Tomás José González-López, MD, Reyes Arranz Sáez, MD, PhD

Blood (2011) 118 (21): 4942.

https://doi.org/10.1182/blood.V118.21.4942.4942

Published: 2011

Journal Articles

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Maria José Requena, Concepción Alaez, Adrian Alegre, Reyes Arranz

Blood (2010) 116 (21): 2867.

https://doi.org/10.1182/blood.V116.21.2867.2867

Published: 2010

NARROW

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry

Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center

Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

High Dose Therapy with Autologous Stem Cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 Patients of Geltamo Spanish Group Suggests That FL Might be Cured, Even in High-Risk Patients

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Prognostic Value of Interim PET/CT in Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL). Experience of the Spanish Geltamo Group

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only